Inhibikase Therapeutics, Inc. IKT
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Inhibikase Therapeutics, Inc. (IKT) is a healthcare company listed in the US with a market value of about $213M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -59%.
About Inhibikase Therapeutics
Inhibikase Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. Revenue went from $698468 in 2020 to $260501 in 2023, a decline of about 28.0% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 2228% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $260501 | $123440 | $3M | $698468 |
| Net income | -$48M | -$28M | -$19M | -$18M | -$15M | -$3M |
| Free cash flow | -$28M | -$19M | -$18M | -$18M | -$14M | — |
| EPS (diluted) | $-0.49 | $-1.16 | $-3.16 | $-4.28 | $-4.84 | $-2.09 |
| Net margin | — | — | -7304.7% | -14625.9% | -476.9% | -407.7% |
| ROIC | -30.1% | -30.1% | -136.8% | -66.5% | -30.2% | -22.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $5.55, 265% above the current price; targets range from $1.50 to $8.00; the consensus rating is “Strong buy”; expected EPS is $-0.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Inhibikase Therapeutics pay a dividend?
Not currently.
Is Inhibikase Therapeutics a good stock to buy?
We do not give buy or sell advice. Inhibikase Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.